Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 852 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE V XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx mění část 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx a xxxxx

(Xxxx x xxxxxxxx xxx EHP)

EVROPSKÁ XXXXXX,

x xxxxxxx na Smlouvu x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx na xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o klasifikaci, xxxxxxxxxx a xxxxxx xxxxx a směsí, x změně a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x změně xxxxxxxx (XX) č. 1907/2006 (1), x xxxxxxx xx xx. 37 xxxx. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx důvodům:

(1)

Tabulka 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxx xx základě xxxxxxxx xxxxxxxxxxx x částech 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx („agentura“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Xx základě xxxxxxxxxx&xxxx;(2) x těmto xxxxxxx, které vydal Xxxxx xxx posuzování xxxxx („RAC“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx zrušit xxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx látek. Uvedená xxxxxxxxxx xxxxxx RAC xxxx:

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx vláken x xxxxxxx křemíku (x xxxxxxx &xx; 3 μx,xxxxx > 5 μx a poměru xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, dioktyl-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 ohledně xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. ledna 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, flupyradifuronu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze dne 8. června 2018 xxxxxxx xxxxxxxxxx kyseliny …%,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx soli, [X-XXX],

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, mecetronium-ethyl-sulfátu [XXX],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [NMA],

—

stanovisko xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx rostliny Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze 30. listopadu 2018 xxxxxxx fosfinu,

—

stanovisko ze xxx 14. xxxx 2018 xxxxxxx dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—

stanovisko ze xxx 30. xxxxxxxxx 2018 ohledně xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (ISO), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx mesotrionu (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko ze xxx 9. března 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx x látku xxxxx (xxxxx XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (olovo x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) a 082–014–00–7 (xxxxxxxx olovo; [průměr xxxxxx ≥ 1 xx];)), XXX ve xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx environmentální xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx rozpouštění xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, ke xxxxxxxxxx xxxxxxx výrobě xxxxxx x xxxxxxxx x xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx forem jiných xxxx v existujících xxxxxxxxx x xxxxxxx XX xxxx XXX xxxxxxx xxxxx xxxxxxxxx xxxx, zda xx xxx na celistvou x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikace. Kromě xxxx byly xxxxxxxxxx xxxx vědecké xxxxxxxx, x xxxxx vyplývá, xx environmentální xxxxxxxxxxx xxx xxxxxxxxx xxxxx, xxx xx doporučilo xxxxxxxxxx xxxxxx RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx formu xxxxx xxxxxx zařazena xx xxxxxxx XX nařízení (XX) x. 1272/2008, xxxxx XXX xxxxxx xxx možnost xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx jde x xxxxx 2-butoxyethanol, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (číslo CAS 111-76-2), xxx třídu xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx RAC, xxx xx xxxxxxx xx xxxxxxxx xxxxxxx, nemusí xxx xxxxxx. Tato xxxxx xxxxxxxxxxxxx by xxxxx neměla být x příloze XX xxxxxxxx (XX) x. 1272/2008 xxxxxxx, xxxxx XXX xxxxxx mít xxxxxxx xxxxxxxxx x xxxxx novým xxxxxxxxxx xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx výboru RAC, xx xxxxxxxx být xxxx.

(5)

Xxxxxxxx (XX) č. 1272/2008 by xxxxx xxxx být xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx aktualizovaných xxxxxxxxxxxxxxx xxxxxxxxxxx by xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx na xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx látek x xxxxx novým xxxx xxxxxxxxxxx klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Xxxx doba xx xxxxxx nezbytná x xxxx, aby xxxxxxxxxx měli dostatek xxxx xxxxxxxx opatření xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx xxxxxxxxx, které xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx podle xxxxxx nařízení. Xxxx xxxxxxxxx mohou zahrnovat xxxxxxxxx stanovené v xx. 22 odst. 1 xxxx. x) xxxxxxxx Evropského xxxxxxxxxx x Xxxx (ES) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx stanovené x xxxxxx 50 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx xx však xxxx xxx umožněno, xxx mohli xxxx xxxxxxxxxx týkající xx xxxxxxxxxxx, označování a xxxxxx uplatňovat dobrovolně xxxxx xxxx xxxxxxxxxxxxx xxxxxx nařízení. Xx xx x xxxxxxx x přístupem podle xx. 61 odst. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Změny xxxxxxxx (XX) č. 1272/2008

Tabulka 3 v xxxxx 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xx xxxx x xxxxxxx s xxxxxxxx xxxxxx nařízení.

Článek 2

Vstup x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx dvacátým xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx xx ode xxx 1. xxxxxx 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx článku xxxxx xxx xxxxx x směsi klasifikovány, xxxxxxxxxx x xxxxxx x xxxxxxx x xxxxxxxxx (XX) x. 1272/2008 xx znění xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Toto nařízení xx xxxxxxx v xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. xxxxxx 2020.

Xx Komisi

Ursula XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. věst. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 xx dne 18. xxxxxxxx 2006

x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx směrnice 1999/45/ES x x zrušení xxxxxxxx Xxxx (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) č. 1488/94, xxxxxxxx Xxxx 76/769/XXX x směrnic Xxxxxx 91/155/EHS, 93/67/EHS, 93/105/XX x 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012 ze xxx 22. xxxxxx 2012

x dodávání xxxxxxxxxx xxxxxxxxx na trh x jejich xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 v xxxxx 3 mění xxxxx:

1)

Xxxxxxxx xx tyto položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx symbolů x xxxxxxxxxx slov

Kódy standardních xxx x nebezpečnosti

Kódy xxxxx. standardních vět x nebezpečnosti

„007-030-00-3

kyselina dusičná …% [C ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 A; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx, xxxxx &xx; 5 μx x s poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Acute Xxx. 3

STOT SE 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 xx; xxxxx částic: xx 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Tox. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (játra)

H318

H410

orální: ATE = 360 mg/kg XX

X = 1

X = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1X

XXXX XX 1

X360X

X372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: C ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Tox. 4

XXXX XX 2

Xxxxxxx Xxxxxxx 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; tetraglym

205-594-7

143-24-8

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: ATE = 3,13 xx/x (prach xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Sens. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Tox. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Liq. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1C

Eye Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx kyselina …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX SE 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 xx/x (prach xxxx mlha)

orální: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Xxxxx Xxx. 3

XXXX RE 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Aquatic Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Xxxx. 1

Xxx Dam. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1 000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1B

Acute Xxx. 2

Xxxxx Xxx. 3

STOT XX 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: ATE = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx TH

M = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 mg/kg TH

M = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Tox. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 xx/x (xxxxx xxxx mlha)

orální: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Eye Xxxxx. 2; X319: 0,025 % ≤ X < 3 %

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

M = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 A; H317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

H350

H340

H372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx lisovaný za xxxxxxx xx xxxxx xxxxxxxx Azadirachta xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

X412

X412“

2)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x kategorií xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Xxx. 2; H272: X ≥ 99 %

Ox. Xxx. 3; H272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

H410

GHS08

GHS09

Wng

H361f ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

XXXX RE 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H302

H372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Press. Xxx

Xxxxx Tox. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Chronic 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 X: C ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx systém)

H410“

„082-013-00-1

olověný xxxxxx; [xxxxxx xxxxxx < 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 mg/kg XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 mg/kg XX orální: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Aquatic Chronic 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach nebo xxxx)

X = 10

M = 10“

„607-314-00-2

ethofumesát (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Xxxxx Tox. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: ATE = 300 mg/kg XX xxxxxx: ATE = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, nervový systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: ATE = 311 xx/xx TH xxxxxx: XXX = 125 xx/xx TH

Skin Xxxx. 1 X; X317: X ≥ 0,0015 %

M = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Repr. 2

Xxxxxxx Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx směs: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; orální, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 xx/xx TH

M = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

XXXX SE 3

XXXX XX 1

XXXX XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní dýchací xxxxx)

X373 (krevní oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx XX orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.